NewswireToday - /newswire/ -
Palo Alto, CA, United States, 2006/03/06 - New analysis from Frost & Sullivan (pharma.frost.com), Global Vaccines Markets, reveals that vaccines markets earned revenue of $ 9,925.5 million in 2005 and estimates to reach $20,019.1 million in 2012..
There is a huge unmet need in emerging markets, which can been catered to only with a focused approach, driven by support from the leading vaccine manufacturers and increased role of private-public partnerships.
New analysis from Frost & Sullivan (pharma.frost.com), Global Vaccines Markets, reveals that vaccines markets earned revenue of $ 9,925.5 million in 2005 and estimates to reach $20,019.1 million in 2012.
If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants an overview of the latest analysis of the Global Vaccines Markets, then send an email to Melina Trevino, Corporate Communications at melina.trevino[.]frost.com with your full name, company name, title, telephone number, fax number and email. Upon receipt of the above information, an overview will be sent to you by e-mail.
"There is a huge shortfall in manufacturing capacity of vaccine manufacturers largely because of the deadlock between governments and vaccine manufacturers. Significant addition to manufacturing capacity is urgently needed to continue immunization programs, especially with new and better vaccines expected to be launched," notes Frost & Sullivan Research Analyst Barath Shankar.
The launch of new vaccines against rotavirus and HPV expects to support the next phase of accelerated growth of the vaccines in developed markets. However, the success of these products in rest of world markets would determine the long-term growth of the vaccines market.
The lack of basic healthcare infrastructure in emerging economies is a major challenge that is receiving increased attention from government and aid agencies. The emergence of private-public partnerships is expected to overcome the hurdles posed by these shortcomings.
"The top five vaccine manufacturers account for 85.3 percent of vaccine revenues globally in 2005. This is due to the large share of revenues from developed markets that account for 79.5 percent of the global vaccine revenues," explains Barath Shankar. "The emerging markets have a large untapped potential that is assisted aid agencies and public-private partnerships."
Increased support from the big-five vaccine manufacturers is needed to ensure growth of vaccines in these markets. The launch of vaccines that have been successful in developed markets and are expensive to manufacture should be launched in emerging markets, with support from regional vaccine manufacturers.
Global Vaccines Markets, a part of the pharmaceuticals and biotechnology subscription service, provides an overview and outlook for the market. This study has been segmented across North America, Europe and Rest of World. This research includes detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.